
Danaher Corporation
DHRNYSEHealthcareMedical - Diagnostics & Research
前收盤價
US$218.85
+US$2.94 · +1.36%
DHR公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Buy
Favorable setup — positive multi-factor alignment
估值
69
Undervalued
動能
48
Neutral
情緒
68
Bullish
風險韌性
70
Moderate Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
- 產業
- Medical - Diagnostics & Research
- 部門
- Healthcare
- 總部
- US
- 執行長
- Rainer Blair
- 上市以來
- 1978年12月29日
- 僱員
- 59,000
市場位置
日內區間
目前US$218.85,
52週區間
目前US$218.85,
- 開盤價
- US$215.19
- 前收盤價
- US$215.91
- 成交量
- 399.98萬
- 0.8× 平均值
- 平均成交量
- 500.64萬
- 日均成交量
- 市值
- 1538.48億 USD
- 貝塔
- 0.8
- 市場參考 1
- 50天平均值
- US$195.43
- 高於平均水平+11.98%
- 200天平均值
- US$202.97
- 高於平均水平+7.82%
財務數據
財務快照
最近十二個月估值與收益率
- 本益比(TTM)
- 38.73×
- 股價淨值比(TTM)
- 2.94×
- 股價營收比(TTM)
- 6.13×
- 股息率
- 0.66%
獲利能力和效率
- 毛利率
- 58.51%
- 營業利益率
- 20.42%
- 淨利潤率
- 15.95%
財務健康
- 負債權益比
- 0.51×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 245.68億 USD | 238.75億 USD | 238.9億 USD | 266.43億 USD | 294.53億 USD |
| 銷貨成本 | 95.98億 USD | 96.69億 USD | 98.56億 USD | 104.55億 USD | 115.01億 USD |
| 毛利 | 149.7億 USD | 142.06億 USD | 140.34億 USD | 161.88億 USD | 179.52億 USD |
| 研究與開發 | 15.98億 USD | 15.84億 USD | 15.03億 USD | 15.28億 USD | 17.42億 USD |
| 銷售、一般及管理費用 | 82.35億 USD | 74.38億 USD | 72.52億 USD | 71.24億 USD | 81.6億 USD |
| 營業費用 | 98.33億 USD | 90.22億 USD | 87.55億 USD | 86.52億 USD | 99.02億 USD |
| 利息收入 | 3000萬 USD | 1.17億 USD | 3.03億 USD | 4100萬 USD | 1100萬 USD |
| 利息支出 | 2.65億 USD | 2.78億 USD | 2.89億 USD | 2.07億 USD | 2.41億 USD |
| 折舊和攤銷 | 24.47億 USD | 23.52億 USD | 21.66億 USD | 21.32億 USD | 21.68億 USD |
| 營業利益 | 51.37億 USD | 51.84億 USD | 52.79億 USD | 75.36億 USD | 80.5億 USD |
| 淨利 | 36.14億 USD | 38.99億 USD | 47.64億 USD | 72.09億 USD | 64.33億 USD |
公司資料更新於 2026年8月24日。
DHR同業公司
持有DHR的ETF
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI39.55億0.17%2.3兆 USD0.03%US$378.24+0.44%
Vanguard S&P 500 ETFVOO32.24億0.19%1.7兆 USD0.03%US$703.71+0.39%
iShares Core S&P 500 ETFIVV18.33億0.21%8918.41億 USD0.03%US$769.31+0.39%
State Street SPDR S&P 500 ETFSPY16.88億0.21%8178.67億 USD0.09%US$765.72+0.41%
Vanguard Morningstar Value ETFVTV11.83億0.46%2565億 USD0.03%US$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV9.78億2.19%447.58億 USD0.08%US$174.62+1.29%
Vanguard Dividend Appreciation ETFVIG6.95億0.53%1309億 USD0.04%US$243.91+0.69%
Vanguard Health Care ETFVHT3.77億1.80%209億 USD0.09%US$327.7+1.24%
Vanguard Morningstar Total Stock Market ETFVTI- 市場價值
- 39.55億
- 重量
- 0.17%
- AUM
- 2.3兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$378.24+0.44%
Vanguard S&P 500 ETFVOO- 市場價值
- 32.24億
- 重量
- 0.19%
- AUM
- 1.7兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$703.71+0.39%
iShares Core S&P 500 ETFIVV- 市場價值
- 18.33億
- 重量
- 0.21%
- AUM
- 8918.41億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$769.31+0.39%
State Street SPDR S&P 500 ETFSPY- 市場價值
- 16.88億
- 重量
- 0.21%
- AUM
- 8178.67億 USD
- 費用率
- 0.09%
- 價格 / 1日
- US$765.72+0.41%
Vanguard Morningstar Value ETFVTV- 市場價值
- 11.83億
- 重量
- 0.46%
- AUM
- 2565億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV- 市場價值
- 9.78億
- 重量
- 2.19%
- AUM
- 447.58億 USD
- 費用率
- 0.08%
- 價格 / 1日
- US$174.62+1.29%
Vanguard Dividend Appreciation ETFVIG- 市場價值
- 6.95億
- 重量
- 0.53%
- AUM
- 1309億 USD
- 費用率
- 0.04%
- 價格 / 1日
- US$243.91+0.69%
Vanguard Health Care ETFVHT- 市場價值
- 3.77億
- 重量
- 1.80%
- AUM
- 209億 USD
- 費用率
- 0.09%
- 價格 / 1日
- US$327.7+1.24%
繼續GoAI的研究
在 GoAI 中研究DHRresearch.disclaimer





